Cancer Monoclonal Antibodies Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Cancer Monoclonal Antibodies Market covers analysis By Type (Murine Antibodies, Chimeric Antibodies, and Humanized Antibodies); Therapies (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Other Monoclonal Antibody Therapies); Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Lung Cancer, and Others), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00004907
  • Category : Life Sciences
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

The Cancer Monoclonal Antibodies Market is expected to register a CAGR of 18% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.

This report studies the Cancer Monoclonal Antibodies Market on basis of Application, Type, and Region. The country analysis provides the major markets worldwide. With the market estimates, in US dollars (US$), the report describes the trends, drivers, and challenges in the market. It can be used by all stakeholders who want to gain an edge and make the right decisions in the monoclonal antibody market.

Purpose of the Report

The report Cancer Monoclonal Antibodies Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Cancer Monoclonal Antibodies Market Segmentation

Type

  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies

Therapies

  • Bevacizumab
  • Rituximab
  • Trastuzumab
  • Cetuximab
  • Panitumumab
  • Other Monoclonal Antibody Therapies

Application

  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Lung Cancer

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Cancer Monoclonal Antibodies Market: Strategic Insights

cancer-monoclonal-antibodies-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Cancer Monoclonal Antibodies Market Growth Drivers

  • Rising Cancer Rates and Aging Populations:Globally rising cancer incidence & aging population are major reasons behind the cancer monoclonal antibodies market. In 2020 alone, more than 18 million new cancer cases were reported worldwide, according to the American Cancer Society – and that number will continue to rise in the coming years. Monoclonal antibodies, with their ability to treat specific cancer but with fewer side-effects than chemo, have emerged as the go-to drug for cancers including breast, lung and colon cancer. The cancer rates are increasing and thus the need for highly effective agents such as monoclonal antibodies is increasing, which fuels blood bank market growth.
  • Technology of Antibody Engineering and Design:Innovations in antibody engineering (eg, creating bispecific antibodies or antibody-drug conjugates (ADCs)), likewise propel the market. Such advances augment the specificity and effectiveness of monoclonal antibodies and thus make it possible to use these to fight cancer. The FDA-approved bispecific antibody Blincyto, for instance, has been a huge success against leukemia. New antibody technologies are helping cancer patients, according to the National Cancer Institute (NCI), and they are raising the need for monoclonal antibodies to combat cancer.
  • Rising Investment in Cancer Research: Increased funding and investment in cancer research by governments, pharmaceutical companies, and private organizations have accelerated the development of new cancer treatments, including monoclonal antibodies. Research into cancer immunotherapy and targeted therapies is helping to identify new targets for monoclonal antibody drugs.

Cancer Monoclonal Antibodies Market Future Trends

  • Cancer Treatment, Precision Medicine, and the Future of Cancer Therapy:
    One of the biggest trends that is likely to influence the cancer monoclonal antibodies market in the future is the transformation to targeted cancer therapy with precision medicine. Precision medicine develops treatments based on the patient’s genetic information so that more specific treatments can be administered. In the case of patients with cancer, monoclonal antibodies are being used in combination with genomic profiling to develop tailored treatment regimens. Molecular diagnostics and tailored treatment will rise and precision medicine will be more than 11 percent more profitable every year by 2020, says the National Institutes of Health (NIH). This is the trend that will propel important monoclonal antibody treatments and clinical use of them.
  • Combination Therapies for Enhanced Efficacy:
    We are now seeing the era of combination therapies in cancer care, where monoclonal antibodies complement another treatment like chemotherapy, immunotherapy or targeted therapy. Combination therapies are improving in the trials, particularly for rare and hard-to-treat cancers. Combining monoclonal antibodies with immune checkpoint inhibitors, for example, have been promising at encouraging immune responses to cancer. Combination immunotherapies are the current gold standard in cancer treatment, with monoclonal antibodies increasingly appearing in combination treatments, as the European Society for Medical Oncology (ESMO) says.
  • Focus on Immuno-oncology: Immuno-oncology is one of the most significant trends in cancer treatment. Monoclonal antibodies, as a form of immunotherapy, are being increasingly studied for their ability to stimulate the immune system to recognize and destroy cancer cells.

Cancer Monoclonal Antibodies Market Opportunities

  • Expanding in Emerging Markets: Cancer, whose incidence in emerging markets is rising, is another huge opportunity in the monoclonal antibodies market. Asia-Pacific, Latin America and the Middle East all have increasing cancer incidences but have better healthcare systems and better treatments. As these countries are developing healthcare infrastructure, monoclonal antibodies market size and share will increase. Cancer is the second leading cause of death in low- and middle-income countries, the WHO states, so monoclonal antibody therapies are needed.
  • Explosion of Biosimilars in Cancer Therapy: Increasing use and approval of biosimilars in the treatment of cancer is another major growth driver for the cancer monoclonal antibodies market. Biosimilars are biologic drugs very similar to reference monoclonal antibodies, but cheaper. The rise of biosimilars should also lower the price of cancer therapies, particularly in low- and middle-income countries. While patents on blockbuster monoclonal antibodies such as Rituxan and Herceptin are expiring, biosimilars are becoming available to increase market share. The FDA says there are now a total of 560 approved biosimilars and this will keep driving the treatment options and the blood bank market growth.
  • Developing mAbs for Rare Cancers: There is a growing opportunity to develop monoclonal antibodies for rare cancers, which often have limited treatment options and are under-researched. By focusing on rare cancers, biotech companies can address an underserved market.

Cancer Monoclonal Antibodies Market Regional Insights

The regional trends and factors influencing the Cancer Monoclonal Antibodies Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cancer Monoclonal Antibodies Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

cancer-monoclonal-antibodies-market-global-geography
  • Get the Regional Specific Data for Cancer Monoclonal Antibodies Market

Cancer Monoclonal Antibodies Market Report Scope

Report Attribute Details
Market size in 2023 US$ XX Million
Market Size by 2031 US$ XX Million
Global CAGR (2023 - 2031) 18%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Type
  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies
By Therapies
  • Bevacizumab
  • Rituximab
  • Trastuzumab
  • Cetuximab
  • Panitumumab
  • Other Monoclonal Antibody Therapies
By Application
  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Lung Cancer
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Amgen Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals, Inc.

  • Cancer Monoclonal Antibodies Market Players Density: Understanding Its Impact on Business Dynamics

    The Cancer Monoclonal Antibodies Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the Cancer Monoclonal Antibodies Market are:

    1. Amgen Inc.
    2. Thermo Fisher Scientific Inc.
    3. F. Hoffmann-La Roche Ltd
    4. Bristol-Myers Squibb Company
    5. GlaxoSmithKline Plc

    Disclaimer: The companies listed above are not ranked in any particular order.


    cancer-monoclonal-antibodies-market-speedometer

    • Get the Cancer Monoclonal Antibodies Market top key players overview

    Key Selling Points

    • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Cancer Monoclonal Antibodies Market, providing a holistic landscape.
    • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
    • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
    • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

    The research report on the Cancer Monoclonal Antibodies Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What is expected CAGR in the Cancer Monoclonal Antibodies Market?

    The market is expected to register a CAGR of 18% during 2023–2031.

    What are the factors impacting on the Cancer Monoclonal Antibodies Market growth?

    Cancer monoclonal antibodies market is driven by the increasing incidence of cancer, ageing population, and improved antibody engineering (binary antibodies, antibody-drug conjugates) which provide better cures for cancer.

    What are the future trends in Cancer Monoclonal Antibodies Market?

    New development in cancer monoclonal antibodies market will be precision medicine based individual therapy and rising number of combination therapies, improving effectiveness and extending the scope of monoclonal antibody therapy.

    Which are key players in the Cancer Monoclonal Antibodies market?

    Key players in this market are - Amgen Inc, Thermo Fisher Scientific Inc, F Hoffmann La Roche Ltd, Bristol Myers Squibb Company, GlaxoSmithKline Plc, Johnson and Johnson Services Inc, Novartis AG, Eli Lilly and Company, Spectrum Pharmaceuticals Inc

    What are the deliverable formats of the Cancer Monoclonal Antibodies market report?

    The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

    What are the options available for the customization of this report?

    Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies

    1. Amgen Inc.
    2. Thermo Fisher Scientific Inc.
    3. F. Hoffmann-La Roche Ltd
    4. Bristol-Myers Squibb Company
    5. GlaxoSmithKline Plc
    6. Johnson and Johnson Services, Inc.
    7. Novartis AG
    8. Eli Lilly and Company
    9. Spectrum Pharmaceuticals, Inc.
    10. Pfizer Inc
    11. Genmab
    12. Seattle Genetics
    13. Takeda Pharmaceutical Company Ltd
    14. Fresenius Kabi AG,
    15. Sanofi
    16. AstraZeneca Plc
    17. Abbvie Inc.

    Buy Now